1-3 of 3
Kaida Wu, PhD
Close
Sort by
Journal Articles

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Catriona HM Jamieson, MD, PhD, Robert P Hasserjian, MD, Jason Gotlib, MD, MS, Jorge E. Cortes, MD, Richard M. Stone, MD, Moshe Talpaz, MD, Jürgen Thiele, MD, PhD, Scott J Rodig, MD, PhD, Abhay Patki, PhD MBA, Kaida Wu, PhD, MD, Jingyang Wu, MSc, Olga Pozdnyakova, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2823.
https://doi.org/10.1182/blood.V122.21.2823.2823
Published: 2013
Journal Articles

A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cdk4/6.

Linda B. Baughn, PhD, Maurizio Di Liberto, PhD, Kaida Wu, PhD, Peter Toogood, PhD, Tracey Louie, Rachel Gottschalk, Ruben Niesvizky, MD, Hearn J. Cho, MD, PhD, Scott Ely, MD, MPH, Malcolm A.S. Moore, D Phil, Selina Chen-Kiang, PhD
Journal: Blood
Blood (2006) 108 (11): 369.
https://doi.org/10.1182/blood.V108.11.369.369
Published: 2006
Journal Articles

Aberrant Autocrine and Paracrine CD40L Signaling Promotes Primary Myeloma Cell Survival and Attenuates Bortezomib-Induced Apoptosis.

Selina Chen-Kiang, PhD, Scott Ely, MD, MPH, Maurizio Di Liberto, PhD, Kaida Wu, PhD, John Shaughnessy, PhD, Malcolm Moore, DPhil, Ruben Niesvizky, MD, Eunice Hatada, PhD
Journal: Blood
Blood (2005) 106 (11): 1564.
https://doi.org/10.1182/blood.V106.11.1564.1564
Published: 2005